Soltis Investment Advisors LLC raised its holdings in Medtronic PLC (NYSE:MDT – Free Report) by 26.5% during the third quarter, HoldingsChannel reports. The firm owned 167,746 shares of the medical technology company’s stock after acquiring an additional 35,100 shares during the quarter. Medtronic accounts for 0.7% of Soltis Investment Advisors LLC’s holdings, making the stock its 22nd largest position. Soltis Investment Advisors LLC’s holdings in Medtronic were worth $14,475,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of the business. BlackRock Inc. raised its holdings in shares of Medtronic by 0.7% during the 2nd quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock worth $8,919,846,000 after buying an additional 838,220 shares in the last quarter. State Street Corp lifted its position in shares of Medtronic by 2.7% during the 2nd quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock worth $5,005,320,000 after buying an additional 1,658,301 shares during the last quarter. Bank of America Corp DE boosted its stake in Medtronic by 5.4% in the first quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock valued at $2,254,200,000 after buying an additional 1,343,220 shares in the last quarter. First Eagle Investment Management LLC boosted its stake in Medtronic by 37.2% in the second quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock valued at $1,078,321,000 after buying an additional 3,739,288 shares in the last quarter. Finally, WCM Investment Management LLC acquired a new stake in Medtronic in the first quarter valued at about $965,922,000. Institutional investors and hedge funds own 82.06% of the company’s stock.
Medtronic Stock Up 2.3%
Shares of MDT opened at $96.92 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33. The stock has a market capitalization of $123.98 billion, a price-to-earnings ratio of 16.57, a PEG ratio of 2.22 and a beta of 0.55. The stock has a fifty day moving average of $91.62 and a 200-day moving average of $88.35.
Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. During the same quarter in the previous year, the company posted $1.26 EPS. Medtronic’s quarterly revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, sell-side analysts anticipate that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.
Medtronic Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Friday, October 16th. Stockholders of record on Friday, September 25th were paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend was Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is presently 70.94%.
Insider Activity
In related news, CEO Geoffrey Martha sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $95.00, for a total value of $4,750,000.00. Following the completion of the transaction, the chief executive officer owned 277,866 shares in the company, valued at $26,397,270. This trade represents a 15.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the transaction, the executive vice president owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. This trade represents a 3.40% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 61,903 shares of company stock valued at $5,889,203. 0.27% of the stock is currently owned by corporate insiders.
Trending Headlines about Medtronic
Here are the key news stories impacting Medtronic this week:
- Positive Sentiment: Exchange-traded funds purchased approximately $18 million of Medtronic shares on October 26, providing a potentially supportive source of demand and signaling institutional interest. ETFs Bought $18.0 Million of Medtronic
- Positive Sentiment: Analyst commentary highlighted Medtronic’s broader growth opportunities and described its valuation as attractive, supporting the case for the stock as a relatively defensive medical-technology investment. Medtronic: Broader Growth, Attractive Valuation
- Positive Sentiment: Medtronic gained even as the overall market dipped, suggesting investors viewed the company’s defensive characteristics and medical-device exposure favorably. Why the Market Dipped But Medtronic Gained Today
- Neutral Sentiment: Upcoming second-quarter fiscal 2027 results are drawing attention. Analysts reportedly expect a low-single-digit decline in profit, making management’s guidance and performance in key growth businesses important near-term catalysts. Medtronic’s Q2 2027 Earnings: What to Expect
- Neutral Sentiment: Comparisons with other medical-device companies, including STERIS, and reviews of Medtronic’s historical shareholder returns provide context but do not identify a new fundamental catalyst. What Have Medtronic Stock Holders Really Earned?
Analyst Ratings Changes
A number of research analysts have issued reports on the company. Wells Fargo & Company lifted their target price on Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a research report on Wednesday, September 2nd. Truist Financial reissued a “hold” rating and issued a $99.00 target price (up from $86.00) on shares of Medtronic in a report on Wednesday, September 2nd. TD Cowen restated a “buy” rating and issued a $110.00 price target on shares of Medtronic in a research note on Wednesday, September 30th. Robert W. Baird lifted their price target on shares of Medtronic from $91.00 to $100.00 and gave the company a “neutral” rating in a report on Wednesday, September 2nd. Finally, UBS Group reaffirmed a “cautious” rating on shares of Medtronic in a report on Wednesday, October 14th. Eighteen research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.88.
Get Our Latest Analysis on MDT
Medtronic Company Profile
Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.
The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.
Featured Articles
- Five stocks we like better than Medtronic
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
